Why FDA Rejects Your CAPA: 5 CAPA Effectiveness Failures Explained

Nearly nine out of ten human-drug warning letters include at least one inadequate CAPA response. Your corrective action plan is the single most rejected document in FDA enforcement — and it's not for lack of effort. Marcus and Priya count down the five CAPA effectiveness failures that keep quality teams in warning-letter territory: fixing the event instead of the system, root causes that stop at human error, CAPAs closed with no proof they worked, CAPAs written to answer the 483 instead of fixing the system, and no trending — so the failure recurs. • Why CAPA is the most rejected document in FDA enforcement • Failure one: corrective action with no preventive action — fixing the event, not the system • Failure two: root causes that stop at "human error" • Failure three: closing a CAPA with zero evidence the change worked • Failure four: CAPAs written to answer the 483 observation, not to fix the system • Failure five: no trending — the same failure recurs, and FDA cites recurrence • The Monday-morning CAPA playbook that survives an investigator Chapters: 0:00 Intro 0:49 The stat that should change your CAPA review 1:40 Failure one — fixing the event, not the system 2:57 Failure two — the root cause that stops at human error 4:56 Failure three — closing CAPA with no proof it worked 6:36 Failure four — CAPA that answers the 483, not the system 10:07 Failure five — no trending, so the failure recurs 11:48 The Monday-morning playbook New discussions every Tuesday and Thursday — subscribe for pharma QA leadership that moves the needle:    / @thegmpinsider   Connect with Tushar Arora on LinkedIn:   / tushar-a-926382161   #CAPA #PharmaQuality #GMP #QualityAssurance #FDA #WarningLetter